Go Deep
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,265 | -8.7 | 3.01 | 0.15 | 340.94 |
| Oct 2026 | 20,342 | -8.6 | 2.95 | 0.15 | 333.27 |
| Oct 2026 | 20,098 | -9.3 | 3.14 | 0.15 | 354.20 |
| Oct 2026 | 20,220 | -8.8 | 3.05 | 0.15 | 342.87 |
| Oct 2026 | 19,866 | -9.6 | 3.31 | 0.15 | 373.58 |
| Oct 2026 | 19,677 | -10.0 | 3.46 | 0.15 | 389.70 |
| Oct 2026 | 19,666 | -10.0 | 3.47 | 0.15 | 389.68 |
| Oct 2026 | 19,794 | -9.8 | 3.37 | 0.15 | 378.04 |
| Oct 2026 | 19,844 | -9.7 | 3.33 | 0.15 | 375.34 |
Taysha Gene Therapies, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 5,485,000.0 | 0.0 |
| Net Profit | -46,639,000.0 | -42,410,000.0 | -27,851,000.0 | -32,733,000.0 |
| EPS | -0.1 | -0.1 | — | -0.1 |
Taysha Gene Therapies, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 9,773,000.0 | 8,333,000.0 | 15,451,000.0 | 2,502,000.0 |
| Net Profit | -108,995,000.0 | -89,298,000.0 | -111,566,000.0 | -166,014,000.0 |
| EPS | -0.3 | -0.4 | -1.0 | -3.8 |
Taysha Gene Therapies, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 343,320,000.0 | 160,364,000.0 | 172,731,000.0 | 126,276,000.0 | — |
| Total Liabilities | 96,382,000.0 | 88,839,000.0 | 97,794,000.0 | 125,327,000.0 | — |
| Total Equity | 246,938,000.0 | 71,525,000.0 | 74,937,000.0 | 949,000.0 | — |
Owes vs Owns
Taysha Gene Therapies, Inc. owed $0.18 for every $1 it owned in Jun 2026, down from $0.99 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.18× | 0.28× | 0.55× | 0.57× | 0.99× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Taysha Gene Therapies, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 93.1%Fixed assets (tangible) 4.7%Other assets 2.1%
How it's funded — Dec 2025
Short-term debt 0.5%Long-term debt 14.6%Payables 1.8%Other liabilities 11.1%Shareholders' equity 71.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 319.8 | 139.0 | 143.9 | 87.9 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 16.2 | 15.9 | 20.4 | 25.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 7.4 | 5.5 | 8.4 | 12.5 |
| Liabilities & equity | ||||
| Short-term debt | 1.9 | 1.9 | 1.6 | 1.5 |
| Long-term debt | 50.1 | 43.9 | 40.5 | 38.0 |
| Payables | 6.3 | 3.6 | 6.4 | 10.9 |
| Other liabilities | 38.1 | 39.4 | 49.3 | 74.9 |
| Shareholders' equity | 246.9 | 71.5 | 74.9 | 0.9 |
| Net tangible assets | 246.9 | 71.5 | 74.9 | 0.9 |
Taysha Gene Therapies, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -93,090,000.0 | -81,225,000.0 | -73,018,000.0 | -88,390,000.0 | — |
| Investing Activities | -604,000.0 | -363,000.0 | -7,352,000.0 | -24,930,000.0 | — |
| Financing Activities | 274,589,000.0 | 76,684,000.0 | 136,393,000.0 | 52,097,000.0 | — |